Cecilia Boutini
GSK PLC is expected to report fourth quarter results on February 1st. Here’s what you should know:
Sales forecast: The UK pharmaceutical giant’s sales are expected to fall to £7.07 billion ($8.73 billion) from £9.35 billion a year earlier, according to consensus provided by the company.
Operating profit/EPS forecast: Operating profit for the fourth quarter is expected to be £1,490m, up from £895m last year, according to the company’s consensus.
Earnings per share are expected to be 21.2p, up from 14.7p last year, according to consensus provided by the company.
What to watch:
– SHINGRIX: The company’s best-selling shingles vaccine is expected to sell £748m in the fourth quarter, according to company consensus. Analysts at UBS said investors will keep a close eye on SCHOTT’s prescription trends and performance after a strong third quarter.
– Guidance: GSK expects 2022 sales to grow between 8% and 10% and adjusted operating profit to grow between 15% and 17% at constant exchange rates excluding Covid-19 solutions I expect. For 2023, UBS analysts said in a note that the company should lead to 5% to 7% sales and EBIT growth at constant exchange rates excluding Covid-19.
Email Cecilia Butini at cecilia.butini@wsj.com.
